# Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

> **NCT02401347** · PHASE2 · COMPLETED · sponsor: **Melinda Telli** · enrollment: 21 (actual)

## Conditions studied

- Advanced Breast Cancer
- HER2/Neu Negative
- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Talazoparib Tosylate

## Key facts

- **NCT ID:** NCT02401347
- **Lead sponsor:** Melinda Telli
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2019-12-23
- **Final completion:** 2022-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02401347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02401347, "Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02401347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*